| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Hypoxia | D000860 | 23 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
| Neovascularization, Pathologic | D009389 | 39 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- J. Lipid Res. (5)
- Proc. Natl. Acad. Sci. U.S.A. (2)
- Am. J. Physiol. Gastrointest. Liver Physiol. (2)
- Others (26)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Imagawa M et al. | Modulation of platelet-activating factor synthesis by recombinant interferon-alpha in human renal cell carcinoma. | 1996 | Urol. Int. | pmid:8840484 |
| Mehta A and Sigman M | Identification and preparation of sperm for ART. | 2014 | Urol. Clin. North Am. | pmid:24286775 |
| Yildirim G et al. | Effects of platelet-activating factor and hyperbaric oxygenation on antioxidant defense and duodenal contractility. | 2000 | Undersea Hyperb Med | pmid:11191161 |
| Vavilova GL et al. | [The role of the thrombocyte-activating factor in inhibiting Na+,K(+)-ATPase in different tissues after ischemia and reperfusion of the small intestine]. | 1996 Mar-Apr | Ukr. Biokhim. Zh. | pmid:9005660 |
| Hansen JF and Hansen BF | [Unstable angina pectoris, acute myocardial infarct, sudden heart death. Patho-anatomy and pathophysiology]. | 1987 | Ugeskr. Laeg. | pmid:3324429 |
| Kabasakal C et al. | The role of PAF and leukotrienes in bioincompatibility of cuprophane membranes in hemodialysis. | 1998 Jul-Sep | Turk. J. Pediatr. | pmid:9763906 |
| Harputluoglu MM et al. | The effects of Gingko biloba extract on acetic acid-induced colitis in rats. | 2006 | Turk J Gastroenterol | pmid:16941250 |
| GamaleÄ IA et al. | [Post-receptor formation of active forms of oxygen in nonphagocytic cells]. | 1999 | Tsitologiia | pmid:10496012 |
| Braquet P et al. | Is there a case for PAF antagonists in the treatment of ischemic states? | 1989 | Trends Pharmacol. Sci. | pmid:2688213 |
| Izzo AA et al. | Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide. | 1998 | Trends Pharmacol. Sci. | pmid:9803830 |
| Page C and Abbott A | PAF: new antagonists, new roles in disease and a major role in reproductive biology. | 1989 | Trends Pharmacol. Sci. | pmid:2672467 |
| GarcÃa-Sáinz JA | Intercellular communication within the liver has clinical implications. | 1989 | Trends Pharmacol. Sci. | pmid:2595791 |
| O'Neill C | A physiological role for PAF in the stimulation of mammalian embryonic development. | 1991 | Trends Pharmacol. Sci. | pmid:2053190 |
| Zimmerman GA and McIntyre TM | PAF, ceramide and pulmonary edema: alveolar flooding and a flood of questions. | 2004 | Trends Mol Med | pmid:15177186 |
| Marathe GK et al. | Oxidized LDL contains inflammatory PAF-like phospholipids. | 2001 Apr-May | Trends Cardiovasc. Med. | pmid:11686003 |
| Chávez-Cartaya RE et al. | Rat liver blood flow after ischemia and reperfusion. The effects of the platelet-activating factor antagonist WEB-2170 and of removing circulating leukocytes. | 1994 | Transplantation | pmid:8197604 |
| Foegh ML et al. | Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. | 1986 | Transplantation | pmid:3523888 |
| Pi F et al. | Effect of a platelet-activating factor antagonist and desferrioxamine administration on eicosanoid production in rat pancreas transplantation. | 1994 | Transplantation | pmid:8291097 |
| Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
| Herrero-Fresneda I et al. | Cold ischemia in the absence of alloreactivity induces chronic transplant nephropathy through a process mediated by the platelet-activating factor. | 2000 | Transplantation | pmid:11190497 |
| Gilli UO et al. | Human polymorphonuclear neutrophils are recruited by porcine chemokines acting on CXC chemokine receptor 2, and platelet-activating factor. | 2005 | Transplantation | pmid:15912099 |
| Freiche JC et al. | Prolonged survival of renal transplants in nonimmunized and hyperimmunized rats receiving a platelet-activating factor antagonist. | 1990 | Transplantation | pmid:2368154 |
| Lanese DM et al. | Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. | 1994 | Transplantation | pmid:7809931 |
| dos Santos OF et al. | Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Glomerular hemodynamics evaluation. | 1989 | Transplantation | pmid:2705209 |
| Makowka L et al. | Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SRI 63-441, on rejection of xenografts and allografts in sensitized hosts. | 1990 | Transplantation | pmid:2402783 |
| Biancone L et al. | Platelet-activating factor synthesis and response on pancreatic islet endothelial cells: relevance for islet transplantation. | 2006 | Transplantation | pmid:16495796 |
| Gu M et al. | Pharmacologic graft protection without donor pretreatment in liver transplantation from non-heart-beating donors. | 2000 | Transplantation | pmid:11045637 |
| Saumweber DM et al. | Hyperacute rejection in an ex vivo model of renal xenografting. Role of the mediator response and its pharmacologic manipulation by the specific platelet-activating factor antagonist WEB 2086BS. | 1994 | Transplantation | pmid:8108870 |
| Biancone L et al. | Role of platelet-activating factor in functional alterations induced by xenoreactive antibodies in porcine endothelial cells. | 2000 | Transplantation | pmid:11063341 |
| Camussi G et al. | Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. | 1987 | Transplantation | pmid:3299910 |
| Yin M et al. | The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. | 1996 | Transplantation | pmid:8633367 |
| Nishiyama R et al. | Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue. | 1993 | Transplantation | pmid:8516812 |
| Kawahara K et al. | The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. | 1993 | Transplantation | pmid:8516834 |
| Takada Y et al. | Effects of platelet-activating factor antagonist on preservation/reperfusion injury of the graft in porcine orthotopic liver transplantation. | 1995 | Transplantation | pmid:7839408 |
| Conte JV et al. | Long-term lung preservation with the PAF antagonist BN 52021. | 1991 | Transplantation | pmid:2048190 |
| Watson CJ et al. | The platelet-activating factor antagonist WEB 2170. Its beneficial effect on dog renal allograft survival. | 1993 | Transplantation | pmid:8212192 |
| Suzuki S et al. | The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion. | 2000 | Transplantation | pmid:10868624 |
| Peyman JA et al. | HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. | 1992 | Transplant. Proc. | pmid:1533073 |
| Pirotzky E et al. | Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN 52063. | 1988 | Transplant. Proc. | pmid:3388505 |
| Kecskemeti V and Balogh I | Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. | 1995 | Transplant. Proc. | pmid:7482928 |
| Yin M et al. | Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7482939 |
| Spiegel HU et al. | Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. | 1995 | Transplant. Proc. | pmid:7482955 |
| Toledo-Pereyra LH and Suzuki S | Cellular and biomolecular mechanisms of liver ischemia and reperfusion injury. | 1994 | Transplant. Proc. | pmid:8109001 |
| Iwamoto H et al. | Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. | 2000 | Transplant. Proc. | pmid:11119873 |
| Da Costa M et al. | Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. | 1990 | Transplant. Proc. | pmid:2389490 |
| Bergmann R et al. | Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. | 1990 | Transplant. Proc. | pmid:2389511 |
| Immunomodulation: other approaches. | 1988 | Transplant. Proc. | pmid:3347955 | |
| Renkonen R et al. | Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. | 1991 | Transplant. Proc. | pmid:1846709 |
| Pignol B et al. | Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. | 1988 | Transplant. Proc. | pmid:3259039 |
| Yin M et al. | Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7879180 |